Refine by
Human Antibodies For Diagnostics Articles & Analysis
11 news found
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced release of its new line of Human Hybrid IgM Control Monoclonal Antibodies for research applications, covering a range of diseases such as CMV, HSV, MeV, MuV, RuV, and VZV.Characteristic disease state sera are serum ...
Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity. Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples ...
This antibody is used for research only, not for human, therapeutic or diagnostic applications. ...
The OPTI SARS-CoV-2 RT-PCR Test has received FDA Emergency Use Authorization and CE-IVD for sample handling using the OPTI Rapid Lysis Buffer. The OPTI Rapid Lysis Buffer protocol eliminates the need for magnetic bead or spin column extraction and prepares the samples for PCR testing using a simple heating protocol. The OPTI Rapid Lysis Buffer has shown a diagnostic sensitivity and specificity of ...
C2N Diagnostics says the U.S. Food and Drug Administration’s (FDA) decision granting accelerated approval to aducanumab (Aduhelm) on the basis of amyloid plaque reduction for Alzheimer’s treatment represents a significant change in the ongoing fight against the horrible disease. Dr. Joel Braunstein, C2N’s CEO, said, “The accelerated approval of aducanumab will offer a ...
C2N Diagnostics, which offers the PrecivityAD™ blood test that can help detect if certain markers for Alzheimer’s disease are in the brain, now has its analytical validation results available for review. The study appears in Clinica Chimica Acta, the official peer-reviewed journal of the International Federation of Clinical Chemistry and Laboratory Medicine. The article is titled ...
A peer-reviewed journal has published the first research paper to state that the PrecivityAD™ blood test “can accurately identify brain amyloid status based on a single blood sample.” The research paper in Molecular Neurodegeneration adds that the test’s “excellent performance” for Alzheimer’s disease (AD) diagnosis allows for “improved medical ...
C2N Diagnostics, which offers the first widely accessible blood test to help physicians with Alzheimer’s disease diagnosis, announces that Rhode Island physicians can now use PrecivityAD™ to aid in the evaluation of their patients showing cognitive impairment. Rhode Island has joined 46 other states, the District of Columbia and Puerto Rico in granting C2N Diagnostics a CLIA ...
Offer price increased from €39.00 to €43.00 per QIAGEN share in cash Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. ...
OPTI Medical Systems, Inc., a subsidiary of IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced that it has received the CE mark certification in the European Union for its OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19. This announcement follows earlier validation of the test by the Institut Pasteur of France as well as Emergency ...
OPTI Medical Systems, Inc., a subsidiary of IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced that the United States Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19. This announcement follows earlier validation of the test by the Institut ...